Groundbreaking Gene Editing Trial for Rare Disease GSD1a Begins at UConn Health and Connecticut Children's

Strategic Insights -

Jennifer Walker UConn Health and Connecticut Children's have made history by dosing the first patient in a clinical trial using gene editing to treat glycogen storage disease type 1a (GSD1a). This global first marks the third "first-in-human" trial for GSD1a conducted by this research team. The therapy uses permanent gene editing to correct a single genetic error, offering a beacon of hope for patients and families worldwide. The trial, led by Rebecca Riba-Wolman, MD, is evaluating a therapy that uses CRISPR-Cas technology to edit a single nucleotide in the patient's liver cells, correcting the underlying disease.

Key Takeaways:

  • The clinical trial is evaluating a therapy that uses permanent gene editing to correct a single genetic error in patients with GSD1a, a rare inherited metabolic disorder.
  • This is the third "first-in-human" trial for GSD1a conducted by this research team and marks a significant milestone in the field of rare disease research.
  • The trial uses CRISPR-Cas technology, a precision technique that earned the Nobel Prize in 2020, to edit a single nucleotide (one of the DNA "letters" A, G, C, or T) that is the basis for the most common mutation causing GSD1a.
  • The therapy has the potential to provide lifelong correction of the underlying disease, making it a significant breakthrough for patients and families affected by GSD1a.
  • The trial is led by Rebecca Riba-Wolman, MD, a pediatric endocrinologist and physician-scientist at both the Connecticut Children's Research Institute and UConn Health.
  • The therapy is based on nucleotide editing and is part of the cutting-edge field born out of the precision technique of CRISPR-Cas genetic editing technology.
  • The trial corrects a single nucleotide that is the basis for the most common mutation causing GSD1a, offering a targeted approach that could allow for lifelong correction of the underlying disease.
  • To date, there exists only one FDA-approved gene editing treatment in the world, for sickle cell disease.
  • The trial has generated excitement among researchers and patients alike, with many families with GSD1a following the progress of the gene editing mouse studies that laid the foundation for this moment.
  • The partnership with Beam Therapeutics builds on decades-long leadership in GSD1a research and is expected to help shape the future of treatment not just for this rare condition, but for all genetic diseases.

Statistics:

  • There are no statistics mentioned in the original text regarding the number of participants, dosing schedules, or expected outcomes.
  • The trial is the third "first-in-human" trial for GSD1a conducted by this research team, marking a significant milestone in the field of rare disease research.
  • The CRISPR-Cas technology used in the trial earned the Nobel Prize in 2020.
  • The trial is being led by Rebecca Riba-Wolman, MD, a pediatric endocrinologist and physician-scientist at both the Connecticut Children's Research Institute and UConn Health.
  • To date, there exists only one FDA-approved gene editing treatment in the world, for sickle cell disease.

Sources:

  • University of Connecticut: Jennifer Walker UConn Health and Connecticut Children's have made history by dosing the first patient in a clinical trial using gene editing to treat glycogen storage disease type 1a (GSD1a).
  • Rebecca Riba-Wolman, MD, quoted in "This is a beacon of hope for patients and their families worldwide, showcasing our commitment to advancing healthcare and saving lives."